8.52
전일 마감가:
$8.61
열려 있는:
$8.63
하루 거래량:
3.32M
Relative Volume:
0.75
시가총액:
$1.78B
수익:
$503.49M
순이익/손실:
$-53.47M
주가수익비율:
-32.77
EPS:
-0.26
순현금흐름:
$-26.89M
1주 성능:
-4.91%
1개월 성능:
-15.64%
6개월 성능:
+11.96%
1년 성능:
+19.33%
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BCRX
Biocryst Pharmaceuticals Inc
|
8.52 | 1.87B | 503.49M | -53.47M | -26.89M | -0.26 |
![]()
ZTS
Zoetis Inc
|
147.37 | 69.30B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 47.50B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.53 | 44.47B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.31 | 18.83B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
293.12 | 13.43B | 2.99B | 1.21B | 1.13B | 25.06 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
2025-02-25 | 개시 | Wedbush | Outperform |
2023-11-20 | 재개 | JP Morgan | Overweight |
2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
2023-02-22 | 업그레이드 | Needham | Hold → Buy |
2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
2021-12-10 | 개시 | Oppenheimer | Outperform |
2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
2021-03-01 | 개시 | Cowen | Outperform |
2020-09-29 | 재개 | JP Morgan | Overweight |
2020-06-17 | 개시 | BTIG Research | Neutral |
2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2018-11-16 | 재개 | Piper Jaffray | Overweight |
2018-08-08 | 재개 | JP Morgan | Overweight |
2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
2018-06-22 | 개시 | Seaport Global Securities | Neutral |
2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2017-12-20 | 개시 | Barclays | Equal Weight |
2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
2016-02-09 | 재확인 | FBR Capital | Outperform |
2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
What analysts say about BioCryst Pharmaceuticals Inc. stockFree Stock Selection - Autocar Professional
BioCryst: ORLADEYO Powers Profitability Amidst Rising HAE Competition (NASDAQ:BCRX) - Seeking Alpha
BioCryst Pharmaceuticals to Announce Q2 2025 Financial Results and Host Conference Call on August 4, 2025 - Quiver Quantitative
BioCryst to Report Second Quarter 2025 Financial Results on August 4 - GlobeNewswire
BioCryst Pharmaceuticals Inc. Stock Analysis and ForecastFree Wealth Management Insights - PrintWeekIndia
What drives BioCryst Pharmaceuticals Inc. stock priceFree Capital Efficiency Planning - Autocar Professional
How To Trade (BCRX) - news.stocktradersdaily.com
BioCryst appoints Babar Ghias as CFO - MSN
Will BioCryst Pharmaceuticals Inc. stock benefit from AI tech trendsCarefully Curated High Return Stocks - beatles.ru
Is BioCryst Pharmaceuticals Inc. a good long term investmentOutstanding stock performance - Jammu Links News
AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies - GlobeNewswire Inc.
Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB - The Globe and Mail
RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 - MSN
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit - GlobeNewswire
BioCryst Unveils Groundbreaking Research on HAE Treatment Burden in Young Patients Under 12 - Stock Titan
Island Pharmaceuticals announces purchase of Galidesivir antiviral program from Biocryst Pharmaceuticals - MarketScreener
Island Pharmaceuticals acquires BioCryst’s Galidesivir - grafa.com
BioCryst Pharmaceuticals appoints Babar Ghias as CFO By Investing.com - Investing.com South Africa
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development - GlobeNewswire
Island Pharmaceuticals Acquires Galidesivir Antiviral Program from BioCryst Pharmaceuticals - AInvest
CFO changes at Biocryst, Xenon, Century, Pyxis - biocentury.com
Missed PDUFA history as Kalvista wins FDA approval for HAE - BioWorld MedTech
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year? - Yahoo
BioCryst Pharmaceuticals (BCRX) Appoints New CFO, Babar Ghias - GuruFocus
BioCryst Pharmaceuticals Appoints Babar Ghias as Chief Financial Officer and Head of Corporate Development - Quiver Quantitative
BioCryst Pharmaceuticals appoints Babar Ghias as CFO - Investing.com
BioCryst Taps Dealmaking Powerhouse as New CFO: $80B Transaction Expert to Drive Growth Strategy - Stock Titan
BioCryst Pharmaceuticals shares rise 1.37% after-hours following the appointment of Babar Ghias as CFO. - AInvest
BioCryst Appoints Babar Ghias Chief Financial Officer and Head o - GuruFocus
BioCryst Pharmaceuticals Sells European ORLADEYO Business for Up to $264M - Insider Monkey
10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Expands Team with 57,000 Share RSU Package: Latest Details on New Hiring Spree - Stock Titan
BioCryst Pharma (BCRX) Receives Boost with Increased Price Target | BCRX Stock News - GuruFocus
BioCryst Pharma (BCRX) Maintains Outperform Rating and $13 Price Target | BCRX Stock News - GuruFocus
BCRX Stock Rating and Price Target Update by Wedbush | BCRX Stoc - GuruFocus
BioCryst Pharma Sells European Business for Rare Disease Drug in $250M Deal - MedCity News
BioCryst to sell European Orladeyo business for up to $264M - MSN
BioCryst Pharmaceuticals (BCRX) Receives Reiterated Buy Rating from Needham | BCRX Stock News - GuruFocus
Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules - BioPharma Dive
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):